Ginkgolide B inhibits renal cyst development in in vitro and in vivo cyst models

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 10, 2012, Pages

  Zhou, Hong ^a   Gao, Jinsheng ^a,b   Zhou, Li ^a   Li, Xin ^a   Li, Weidong ^a   Li, Xuejun ^a   Xia, Yin ^c   Yang, Baoxue ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b Shanxi Province Hospital of Traditional Chinese Medicine   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

ADPKD; MAPK; Natural product

Indexed keywords

G 6910; GINKGOLIDE B; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYST FLUID; DISEASE COURSE; EMBRYO; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SECRETION; SIGNAL TRANSDUCTION;

EID: 84861130194     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00356.2011     Document Type: Article

References (46)

1. Battini L, Fedorova E, Macip S, Li X, Wilson PD, Gusella GL. Stable knockdown of polycystin-1 confers integrin-alpha2beta1-mediated anoikis resistance. J Am Soc Nephrol 17: 3049-3058, 2006.
2. Belibi FA, Edelstein CL. Novel targets for the treatment of autosomal dominant polycystic kidney disease. Expert Opin Investig Drugs 19: 315-328, 2010.
3. Calvet JP. Strategies to inhibit cyst formation in ADPKD. Clin J Am Soc Nephrol 3: 1205-1211, 2008.
4. Calvet JP, Grantham JJ. The genetics and physiology of polycystic kidney disease. Semin Nephrol 21: 107-123, 2001.
5. Fisher CE, Michael L, Barnett MW, Davies JA. Erk MAP kinase regulates branching morphogenesis in the developing mouse kidney. Development 128: 4329-4338, 2001.
6. Galietta LJ, Haggie PM, Verkman AS. Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Let 499: 220-224, 2001.
7. Gao J, Zhou H, Lei T, Zhou L, Li W, Li X, Yang B. Curcumin inhibits renal cyst formation and enlargement in vitro by regulating intracellular signaling pathways. Eur J Pharmacol 654: 92-99, 2011.
8. Gonzalez MV, Montminy MR. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. Cell 59: 611-617, 1989.
9. Grantham JJ, Mangoo-Karim R, Uchic ME, Grant M, Shumate WA, Park CH, Calvet JP. Net fluid secretion by mammalian renal epithelial cells: Stimulation by cAMP in polarized cultures derived from established renal cells and from normal and polycystic kidneys. Trans Assoc Am Physicians 102: 158-162, 1989.
10. Harris PC, Torres VE. Polycystic kidney disease. Annu Rev Med 60: 321-337, 2009.
11. Huang SH, Duke RK, Chebib M, Sasaki K, Wada K, Johnston GA. Ginkgolides, diterpene trilactones of Ginkgo biloba, as antagonists at recombinant alpha1beta2 gamma2L GABAA receptors. Eur J Pharmacol 494: 131-138, 2004.
12. 2+ stimulation of CREB-dependent transcription and ERK nuclear translocation. Neuron 21: 869-883, 1998.
13. Jiang ST, Chuang WJ, Tang MJ. Role of fibronectin deposition in branching morphogenesis of Madin-Darby canine kidney cells. Kidney Int 57: 1860-1867, 2000.
14. Jin GH, Huang Z, Tan XF, Tian ML, Zhang XH, Qin JB, Xu HJ, Yew DT, Mak YT. Effects of ginkgolide on the development of NOS and AChE positive neurons in the embryonic basal forebrain. Cell Biol Int 30: 500-504, 2006.
15. Leonhard WN, van der Wal A, Novalic Z, Kunnen SJ, Gansevoort RT, Breuning MH, de Heer E, Peters DJ. Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model. Am J Physiol Renal Physiol 300: F1193-F1202, 2011.
16. Leuenroth SJ, Bencivenga N, Igarashi P, Somlo S, Crews CM. Triptolide reduces cystogenesis in a model of ADPKD. J Am Soc Nephrol 19: 1659-1662, 2008.
17. Leuenroth SJ, Crews CM. Targeting cyst initiation in ADPKD. J Am Soc Nephrol 20: 1-3, 2009.
18. Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, Crews CM. Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci USA 104: 4389-4394, 2007.
19. Li R, Chen B, Wu W, Bao L, Li J, Qi R. Ginkgolide B suppresses intercellular adhesion molecule-1 expression via blocking nuclear factorkappa B activation in human vascular endothelial cells stimulated by oxidized low-density lipoprotein. J Pharmacol Sci 110: 362-369, 2009.
20. -, co-transporter-dependent cystic dilation. J Am Soc Nephrol 17: 3424-3437, 2006.
21. Mahmoud FF, Haines DD, Abul HT, Abal AT, Onadeko BO, Wise JA. In vitro effects of astaxanthin combined with ginkgolide B on T lymphocyte activation in peripheral blood mononuclear cells from asthmatic subjects. J Pharmacol Sci 94: 129-136, 2004.
22. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5=-cyclic monophosphate. Gastroenterology 132: 1104-1116, 2007.
23. McAteer JA, Dougherty GS, Gardner KD Jr, Evan AP. Scanning electron microscopy of kidney cells in culture: surface features of polarized epithelia. Scan Electron Microsc Pt 3: 1135-1150, 1986.
24. McAteer JA, Dougherty GS, Gardner KD Jr, Evan AP. Polarized epithelial cysts in vitro: a review of cell and explant culture systems that exhibit epithelial cyst formation. Scanning Microsc 2: 1739-1763, 1988.
25. McAteer JA, Evan AP, Gardner KD. Morphogenetic clonal growth of kidney epithelial cell line, MDCK. Anat Rec 217: 229-239, 1987.
26. Murthy M, Pedemonte N, MacVinish L, Galietta L, Cuthbert A. 4-Chlorobenzo[F]isoquinoline (CBIQ), a novel activator of CFTR and DeltaF508 CFTR. Eur J Pharmacol 516: 118-124, 2005.
27. Park EY, Woo YM, Park JH. Polycystic kidney disease and therapeutic approaches. BMB Rep 44: 359-368, 2011.
28. Patel V, Chowdhury R, Igarashi P. Advances in the pathogenesis and treatment of polycystic kidney disease. Curr Opin Nephrol Hypertens 18: 99-106, 2009.
29. Pollack AL, Runyan RB, Mostov KE. Morphogenetic mechanisms of epithelial tubulogenesis: MDCK cell polarity is transiently rearranged without loss of cell-cell contact during scatter factor/hepatocyte growth factor-induced tubulogenesis. Dev Biol 204: 64-79, 1998.
30. Ruggenenti P, Remuzzi A, Ondei P, Fasolini G, Antiga L, Ene- Iordache B, Remuzzi G, Epstein FH. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 68: 206-216, 2005.
31. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 4: 477-485, 1990.
32. Shibazaki S, Yu Z, Nishio S, Thomson RB, Mitobe M, Louvi A, Velazquez H, Ishibe S, Cantley LG, Igarashi P, Somlo S. Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1. Hum Mol Genet 17: 1505-1516, 2008.
33. Sun Y, Zhou H, Yang B. Drug discovery for polycystic kidney disease. Acta Pharmacol Sin 32: 805-816, 2011.
34. Taide M, Kanda S, Igawa T, Eguchi J, Kanetake H, Saito Y. Human simple renal cyst fluid contains a cyst formation-promoting activity for Madin-Darby canine kidney cells cultured in collagen gel. Eur J Clin Invest 26: 506-513, 1996.
35. Torres VE. Cyclic AMP, at the hub of the cystic cycle. Kidney Int 66: 1283-1285, 2004.
36. Torres VE. Vasopressin antagonists in polycystic kidney disease. Semin Nephrol 28: 306-317, 2008.
37. Tradtrantip L, Sonawane ND, Namkung Verkman AS W. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem 52: 6447-6455, 2009.
38. Wang SJ, Chen HH. Ginkgolide B, a constituent of Ginkgo biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminals. Eur J Pharmacol 514: 141-149, 2005.
39. Wilson PD. Polycystic kidney disease: new understanding in the pathogenesis. Int J Biochem Cell Biol 36: 1868-1873, 2004.
40. Xia SH, Fang DC. Pharmacological action and mechanisms of ginkgolide B. Chin Med J (Engl) 120: 922-928, 2007.
41. Xing J, Ginty DD, Greenberg ME. Coupling of the Ras-MAPK pathway to gene activation by RSK2, a growth factor regulated CREB kinase. Science 273: 959-963, 1996.
42. Yamaguchi T, Hempson SJ, Reif GA, Hedge AM, Wallace DP. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells. J Am Soc Nephrol 17: 178-187, 2006.
43. Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int 63: 1983-1994, 2003.
44. Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growthstimulated phenotype. J Biol Chem 279: 40419-40430, 2004.
45. Yang B, Sonawane ND, Zhao D, Somlo S, Verkman AS. Smallmolecule CFTR inhibitors slow cyst growth in polycystic kidney disease. J Am Soc Nephrol 19: 1300-1310, 2008.
46. Ye B, Aponte M, Dai Y, Li L, Ho MC, Vitonis A, Edwards D, Huang TN, Cramer DW. Ginkgo biloba and ovarian cancer prevention: epidemiological and biological evidence. Cancer Lett 251: 43-52, 2007.